KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $286.5 million.

  • CRISPR Therapeutics AG's Cash & Equivalents rose 2695.4% to $286.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $286.5 million, marking a year-over-year increase of 2695.4%. This contributed to the annual value of $298.3 million for FY2024, which is 2342.57% down from last year.
  • According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Cash & Equivalents is $286.5 million, which was up 2695.4% from $193.6 million recorded in Q2 2025.
  • CRISPR Therapeutics AG's 5-year Cash & Equivalents high stood at $1.6 billion for Q2 2021, and its period low was $193.6 million during Q2 2025.
  • In the last 5 years, CRISPR Therapeutics AG's Cash & Equivalents had a median value of $484.5 million in 2024 and averaged $564.8 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 7704.46% in 2022, then skyrocketed by 10540.44% in 2024.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Cash & Equivalents stood at $923.0 million in 2021, then crashed by 77.04% to $211.9 million in 2022, then skyrocketed by 83.83% to $389.5 million in 2023, then dropped by 23.43% to $298.3 million in 2024, then dropped by 3.94% to $286.5 million in 2025.
  • Its Cash & Equivalents stands at $286.5 million for Q3 2025, versus $193.6 million for Q2 2025 and $235.2 million for Q1 2025.